In vitro activity of the new oxazolidinone AZD2563 against Enterococci.
The activity of a new oxazolidinone antimicrobial, AZD2563, was assessed against >500 clinical isolates of enterococci representing six species. All isolates, including those resistant to other antibiotic classes, were inhibited by AZD2563 at concentrations </=2 micro g/ml, except for four strains resistant to linezolid. In most cases, AZD2563 was twofold more active than linezolid against enterococci.
Eliopoulos
G M
GM
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA. geliopou@caregroup.harvard.edu
Wennersten
C B
CB
Moellering
R C
RC
D000081:Acetamides / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D016983:Enterococcus / Q000145:classification / Q000187:drug effects*; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000737:chemistry / Q000494:pharmacology*
D000081:Acetamides; D023303:Oxazolidinones; C453362:posizolid; D000069349:Linezolid